title: [Current state of anti-tumor necrosis factor therapy in autoimmune diseases].
abstract: Tumor necrosis factor (TNF) alpha plays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti-TNF agents (infliximab, etanercept and adalimumab) represents an important tool for the management of a variety of disorders, such as rheumatoid arthritis, the spondyloarthropathies, inflammatory bowel disease and psoriasis. Nonetheless, theoretically, some other autoimmune and inflammatory disorders may benefit from these agents. We intend to update on these off-label uses of anti-TNF blockers in this review.
authors.affiliation: Unidad de Enfermedades Autoinmunes Sistémicas, Hospital Universitario San Cecilio, Granada, Spain. danifilax@gmail.com
authors.forename: Daniel
authors.initials: D
authors.lastname: Sánchez Cano
authors.forename: José Luis
authors.initials: JL
authors.lastname: Callejas Rubio
authors.forename: Norberto
authors.initials: N
authors.lastname: Ortego Centeno
mesh_terms: D001327:Autoimmune Diseases / Q000188:drug therapy*; D006801:Humans; D012871:Skin Diseases / Q000188:drug therapy / Q000276:immunology; D000079424:Tumor Necrosis Factor Inhibitors; D014657:Vasculitis / Q000188:drug therapy / Q000276:immunology
chemical_list: D000079424:Tumor Necrosis Factor Inhibitors